Spero Therapeutics (SPRO) Non-Current Deffered Revenue (2016 - 2025)

Spero Therapeutics (SPRO) has 8 years of Non-Current Deffered Revenue data on file, last reported at $12.6 million in Q3 2025.

• For the quarter ending Q3 2025, Non-Current Deffered Revenue rose 6.12% year-over-year to $12.6 million; the trailing twelve-month figure through Sep 2025 stood at $12.6 million (up 6.12% YoY), and the FY2024 full-year result was $12.2 million, up 12.88% from the prior year.
• Non-Current Deffered Revenue for Q3 2025 stood at $12.6 million, roughly flat from $12.6 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $23.8 million in Q3 2023 and bottomed at $8.8 million in Q4 2021.
• The 5-year median for Non-Current Deffered Revenue is $12.2 million (2024), against an average of $13.5 million.
• The widest annual swing landed in 2024, when Non-Current Deffered Revenue tumbled 59.46%; it then surged 39.1% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $8.8 million in 2021, then advanced by 10.87% to $9.7 million in 2022, then grew by 11.13% to $10.8 million in 2023, then advanced by 12.88% to $12.2 million in 2024, then climbed by 2.91% to $12.6 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $12.6 million (Q3 2025), $12.6 million (Q2 2025), and $12.6 million (Q1 2025), per Business Quant data.

Peer Comparison